臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| Total items :2830311
	Visitors : 32543445 Online Users : 978 Project Commissioned by the Ministry of Education Project Executed by National Taiwan University Library

Scope

Adv. Search

Login

Administrator

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

About TAIR
	About TAIR

Browse By
	Institution
	Author
	Title
	Date
	Statistics Chart
	Institution Facts
	Trend

News
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

Copyright
	Publisher & Journal Policy
	TAIR Copyright Conference Minutes

Related Links
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"oxnard g r"

Return to Browse by Author
Sorting by Title	Sort by Date

Showing items 1-7 of 7 (1 Page(s) Totally)
1
View [10|25|50] records per page

Institution	Date	Title	Author
臺大學術典藏	2021-04-23T05:56:30Z	TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer	Oxnard G.R.;Chih-Hsin Yang;Yu H.;Kim S.-W.;Saka H.;Horn L.;Goto K.;Ohe Y.;Mann H.;Thress K.S.;Frigault M.M.;Vishwanathan K.;Ghiorghiu D.;Ramalingam S.S.;Ahn M.-J.; Oxnard G.R.; CHIH-HSIN YANG; Yu H.; Kim S.-W.; Saka H.; Horn L.; Goto K.; Ohe Y.; Mann H.; Thress K.S.; Frigault M.M.; Vishwanathan K.; Ghiorghiu D.; Ramalingam S.S.; Ahn M.-J.
臺大學術典藏	2020-05-26T09:26:47Z	136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial	Oxnard G.R.;Walding A;Yang L;Kim S.-W;Goto K;Ramalingam S;Saka H;Yu H;Chih-Hsin Yang;Ahn M.-J; Ahn M.-J; CHIH-HSIN YANG; Yu H; Saka H; Ramalingam S; Goto K; Kim S.-W; Yang L; Walding A; Oxnard G.R.
臺大學術典藏	2020-05-26T09:26:47Z	136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial	Oxnard G.R.;Walding A;Yang L;Kim S.-W;Goto K;Ramalingam S;Saka H;Yu H;Chih-Hsin Yang;Ahn M.-J; Ahn M.-J; CHIH-HSIN YANG; Yu H; Saka H; Ramalingam S; Goto K; Kim S.-W; Yang L; Walding A; Oxnard G.R.
臺大學術典藏	2020-05-26T09:26:46Z	135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC	J?nne P.;Chih-Hsin Yang;Barrett C;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; Barrett C; CHIH-HSIN YANG; Jänne P.
臺大學術典藏	2020-05-26T09:26:46Z	135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC	J?nne P.;Chih-Hsin Yang;Barrett C;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; Barrett C; CHIH-HSIN YANG; Jänne P.
臺大學術典藏	2020-05-26T09:26:44Z	Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer	J?nne P.A.;Barrett J.C;Chih-Hsin Yang;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; CHIH-HSIN YANG; Barrett J.C; Jänne P.A.
臺大學術典藏	2020-05-26T09:26:44Z	Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer	J?nne P.A.;Barrett J.C;Chih-Hsin Yang;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; CHIH-HSIN YANG; Barrett J.C; Jänne P.A.

Showing items 1-7 of 7 (1 Page(s) Totally)
1
View [10|25|50] records per page